Arcus Biosciences RCUS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -156.3%-28.4pp | -127.9%+163pp | -290.6%-40.6pp | -250%-264pp | |
| Net margin | -142.9%-33.2pp | -109.7%+153pp | -262.4%-24.0pp | -238.4%-252pp | |
| EBITDA margin | -152.2%-28.2pp | -124%+160pp | -283.8%-39.1pp | -244.6%-260pp | |
| Free cash flow margin | -196%— | —— | -282.1%— | —— | |
| Returns | |||||
| Return on equity | -63.3%-3.5pp | -59.8%-4.9pp | -54.9%-19.2pp | -35.6%-43.5pp | |
| Return on assets | -30.8%-5.6pp | -25.2%0.0pp | -25.2%-7.0pp | -18.2%-22.7pp | |
| Return on invested capital | -70.1%-0.6pp | -69.5%-3.6pp | -65.8%-25.4pp | -40.4%-49.5pp | |
| Efficiency | |||||
| Asset turnover | 0.2×0.0× | 0.2×+0.1× | 0.1×0.0× | 0.1×-0.2× | |
| Liquidity | |||||
| Current ratio | 4.4×-0.1× | 4.5×0.0× | 4.5×-1.0× | 5.5×-2.1× | |
| Quick ratio | 4.4×-0.1× | 4.5×0.0× | 4.5×-1.0× | 5.5×-2.1× | |
| Cash ratio | 1×+0.3× | 0.7×0.0× | 0.7×-0.4× | 1.1×+0.2× | |
| Leverage | |||||
| Debt-to-equity | 0.3×0.0× | 0.3×+0.1× | 0.3×+0.1× | 0.2×+0.1× | |
| Debt-to-assets | 0.2×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Interest coverage | -48.3×+34.3× | -82.5×— | —— | -140×— | |
| Per Share | |||||
| Book value per share | $5.88+9.1% | $5.38-13.8% | $6.24-31.6% | $9.13-19.8% | |
| Valuation | |||||
| Market capitalization | $2.95B+116% | $1.36B-4.9% | $1.43B-4.3% | $1.5B-47.3% | |
| Enterprise value | $2.92B+113% | $1.37B-3.8% | $1.43B+0.6% | $1.42B-49.5% | |
| Price / sales | 11.9×+6.7× | 5.3×-7.0× | 12.2×-1.1× | 13.4×+5.9× | |
| Price / book | 4.7×+1.9× | 2.8×-0.3× | 3.1×+0.8× | 2.3×-1.1× | |
| EV / sales | 11.8×+6.5× | 5.3×-6.9× | 12.2×-0.5× | 12.7×+5.3× | |
| Free cash flow yield | -16.4%— | —— | -23%— | —— | |
| Earnings yield | -12%+8.8pp | -20.8%+0.7pp | -21.4%-3.6pp | -17.8%-19.7pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Arcus Biosciences's ratios come from?
- Every ratio is computed from Arcus Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.